search

Active clinical trials for "Ischemia"

Results 91-100 of 2694

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke

Acute Ischemic Stroke

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Recruiting15 enrollment criteria

Normobaric Hyperoxia Combined With Endovascular Therapy in Patients With Stroke Within 6 Hours of...

StrokeAcute3 more

The overall incidence of good outcome for AIS following endovascular treatment is only proximately 50%. Whether NBO was safe and effective to improve acute ischemic stroke prognosis is still unclear. The investigators' hypothesis is thatNBO is a safe and effective strategy to improve longterm outcome in AIS patients undergoing endovascular treatment.

Recruiting20 enrollment criteria

Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT...

StrokeAcute1 more

Background: Stroke is the third major cause of death and disability worldwide. It was shown that combining early reperfusion therapy (thrombolysis and/or thrombectomy) with stroke unit care and immediate rehabilitation have beneficial effects on the patient recovery and outcomes. Cerebrolysin that was proven to have s neuroprotective and neurotrophic effects in vitro and in vivo, administered in combination with endovascular therapy (EVT) could have a positive impact on the prognosis and outcome of these patients. Objectives: To evaluate the impact of early administration of neuroprotective drug (Cerebrolysin) in patient undergoing EVT on the outcome of patients diagnosed with acute ischemic stroke. Methods: 100 patients will be recruited to the proposed study according to the inclusion criteria: Inclusion criteria: Acute ischemic stroke patients NIHSS>8 Qualification for mechanical thrombectomy, without previous thrombolysis. The patients will be randomized into 2 subgroups: G1(standard dose of Cerebrolysin 30ml), - G2 (No Cerebrolysin). The patients will be randomized into 2 subgroups: G1(standard dose of Cerebrolysin 30ml), - G2 (No Cerebrolysin). Cerebrolysin will be administered immediately after randomization or at the latest during the EVT procedure and will be continued for 10 days. After the EVT all patients, depending on their clinical condition, will be hospitalized in ICU (intensive care unit) or Neurology Department, where standard treatment and monitoring will be implemented, as well as standard rehabilitation. Outcome assessments will include: the NIH Stroke Scale, modified Rankin Score, pre MRS, IQ code, Geriatric Depression Scales, MoCA. Additionally, the infarct volume of the control CT will be measured. The follow up should be performed on day 7( or discharge), 1 month, 3 months, 6 months. The duration of the study is planned forr: 12 -24 months

Recruiting9 enrollment criteria

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke

Acute Ischemic Stroke

The study objective is to examine and compare clinical outcomes, as measured by Modified Rankin Scale (mRS) at 90 days (± 15 days) post treatment, and related performance characteristics of the Envi™-SR and concurrent parallel Control Devices currently cleared by the U.S. FDA for treatment of stroke.

Recruiting44 enrollment criteria

De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease

Stable Ischemic Heart DiseaseCoronary Artery Disease1 more

Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. The study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.

Recruiting15 enrollment criteria

Instantaneous Wave-free Ratio Guidance Strategy Evaluation in the Treatment of Multivessel Acute...

Cardiac IschemiaAcute Coronary Syndrome

A single-center, prospective, randomized, open-label, blinded end-point clinical trial of instantaneous wave-free ratio (iFR) guidance strategy impact on clinical outcomes in multivessel acute coronary syndrome (ACS) patients.

Recruiting16 enrollment criteria

Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance...

Refractory Angina

ORBITA-COSMIC is a randomised, double-blinded, placebo controlled trial of the coronary sinus reducer (CSR). The investigators will compare the effects of CSR versus placebo on myocardial perfusion on MRI, exercise time and symptoms in 50 participants with refractory angina and ischaemia.

Recruiting18 enrollment criteria

Investigation of Huatuo Zaizao Pill in Treating Phlegm and Blood-stasis Blocking Collaterals Pattern...

Ischemic Stroke

This study is aiming to evaluate the efficacy and safety of Huatuo Zaizao pill in ischemic stroke patients who diagnosed as the phlegm and blood-stasis blocking collaterals syndrome in TCM. A total of 80 subjects will be randomly assigned to Huatuo Zaizao pill group or the control group.

Recruiting2 enrollment criteria

SELUTION4BTK Trial

Peripheral Arterial DiseaseChronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

Recruiting64 enrollment criteria

Clinical Trial on Remote Ischemic Conditioning in Acute Ischemic Stroke Within 9 Hours of Onset...

Ischemic Stroke

Phase II, prospective, randomized, multicenter, open-label, pilot clinical trial comparing remote ischemic conditioning (RIC) plus standard medical therapy to standard medical therapy alone, in patients with acute ischemic stroke within 9 hours of stroke onset that are not eligible to recanalization therapies.

Recruiting17 enrollment criteria
1...91011...270

Need Help? Contact our team!


We'll reach out to this number within 24 hrs